ArticleClinical and vaccine immunology : CVI2007
Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England.
Article in Clinical and vaccine immunology : CVI, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 54 citations in OpenAlex.
- Controlled Human Infection of Healthy Adults With LyophilizedOpen forum infectious diseases · 2026Article
- Tiny packages, big potential: bacterial membrane vesicles in vaccinology.Microbial cell factories · 2025Review
- Hybrid response to SARS-CoV-2 andHuman vaccines & immunotherapeutics · 2024Article
- Convergent impact of vaccination and antibiotic pressures on pneumococcal populations.Cell chemical biology · 2024Review
- A recombinant commensal bacteria elicits heterologous antigen-specific immune responses during pharyngeal carriage.Science translational medicine · 2021Article
- Commensal Neisseria Kill Neisseria gonorrhoeae through a DNA-Dependent Mechanism.Cell host & microbe · 2019Article
- Impact of meningococcal group B OMV vaccines, beyond their brief.Human vaccines & immunotherapeutics · 2018Article
- Protection Against Invasive Infections in Children Caused by Encapsulated Bacteria.Frontiers in immunology · 2018Review
- Seroprevalence of bactericidal antibodies against serogroup B and C Meningococci in a University Hospital.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2017Article
- Article
- Seroprevalence of Antibody-Mediated, Complement-Dependent Opsonophagocytic Activity against Neisseria meningitidis Serogroup B in England.Clinical and vaccine immunology : CVI · 2015Article
- Oropharyngeal Colonization With Neisseria lactamica, Other Nonpathogenic Neisseria Species and Moraxella catarrhalis Among Young Healthy Children in Ahvaz, Iran.Jundishapur journal of microbiology · 2015Article
- Meningococcal disease and the complement system.Virulence · 2014Review
- Article
- Seroprevalence of serum bactericidal antibodies against group W135 and Y meningococci in England in 2009.Clinical and vaccine immunology : CVI · 2012Article
- Infections of people with complement deficiencies and patients who have undergone splenectomy.Clinical microbiology reviews · 2010Review
- Review of meningococcal group B vaccines.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2010Review
- Immunodeficiencies.Clinical and experimental immunology · 2009Review
- Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease.Vaccine · 2009Review
- Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity.Clinical and vaccine immunology : CVI · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Outer membrane vesicle (OMV) and recombinant protein-based vaccines targeted against multiple strains of group B meningococci are under development. The serum bactericidal antibody (SBA) assay has been designated the surrogate of protection, but the exact cutoff has not been determined. We measured the SBA titers in 2,415 serum samples and the anti-OMV IgG antibody concentrations in 2,672 serum samples representative of the English population to establish a baseline of natural immunity. SBA and anti-OMV IgG antibody titers are high in infants in the first 3 months of life, declining thereafter, presumably as maternal immunity wanes. About 6% of the subjects in the 1- to 11-year-old age group had SBA titers >or=4. During the teenage years, there was a marked increase in the percentage of subjects with SBA titers >or=4, rising to over 50% in 19-year-olds, with about 20% of older adults achieving this titer. The peak in SBA and anti-OMV IgG titers coincided with the peak in meningococcal carriage. Simple mathematical models confirm that the relationship between observed seroprevalence and carriage by age is consistent with carriage inducing SBA and that following an episode of carriage, SBA levels may remain elevated for many months. With the exception of children aged 3 to 11 months, there was no clear relationship between disease incidence and seroprevalence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.